Invitae Corporation Invitae Corporation

Invitae Corporation

NVTA

Rank in Stocks #35792
Invitae Corporation operates as a medical genetics enterprise, striving to... Invitae Corporation operates as a medical genetics enterprise, striving to integrate genetic insights into mainstream medical practice to enhance healthcare outcomes for individuals in the United States, Canada, and internationally. The company provides a comprehensive suite of offerings, including genetic testing for various clinical specializations such as hereditary cancer, cardiovascular health, neurological disorders, pediatric conditions, oncology, metabolic ailments, and rare diseases, alongside digital health tools and health data services. Its clientele spans individual patients, healthcare providers, biopharmaceutical firms, and other collaborators. Established in 2010 as Locus Development, Inc., the company officially became Invitae Corporation in 2012 and is headquartered in San Francisco, California.
Share Price
$0.016
Last synced: 2024-03-11
Market Cap
$3.27M
Change (1 day)
-5.33%
Change (1 year)
5,233.33%
Country
US
Trade Invitae Corporation (NVTA)

Category

Healthcare
P/B ratio for Invitae Corporation (NVTA)
P/B ratio as of October 2026 TTM: 0.00
According to Invitae Corporation latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0.00. At the end of 2021 the company had a P/B ratio of 1.08.
P/B ratio history for Invitae Corporation from 2012 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
2026 (TTM) 0.00 -99.98%
2022 4.30 298.01%
2021 1.08 -62.15%
2020 2.86 -25.99%
2019 3.86 -15.37%
2018 4.56 31.55%
2017 3.47 30.42%
2016 2.66 58.84%
2015 1.67 -127.59%
2014 -6.07 -10.86%
2013 -6.81 -65.78%
2012 -19.88 0.00%
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
4.7411 592,537.50%
US
3.0143 376,687.50%
US
31.051 3,881,275.00%
US
- -
CN
6.6641 832,912.50%
US